TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

PAR PHARM

DermatologyInfectious DiseaseOncology
Generics

PAR PHARM is a generic drug manufacturer focused on Dermatology, Infectious Disease, Oncology.

1971
Since
51
Drugs
-
Trials
408
Approved (2yr)

Key Drugs

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE
dextromethorphan hydrobromide
NMDA receptor 1 indications · 2017

Recent Activity

LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
DOXYCYCLINE HYCLATE 2026-02-19
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
LATANOPROST 2026-01-30
Labeling
DOXYCYCLINE HYCLATE 2026-01-26
Labeling
CLOZAPINE 2026-01-25
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 31%
1 drugs Phase 3: 2 Phase 1: 1
Infectious Disease 29%
1 drugs Phase 3: 1 Phase 2: 2
Oncology 29%
0 drugs Phase 3: 3 Phase 1: 2
Cardiovascular 12%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology, Cardiovascular
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular